FIGURE 2.
6-phosphogluconate dehydrogenase (6PGD) expression is upregulated in cisplatin-resistant cells and higher 6PGD gene expression correlates with reduced survival of cancer patients. (A) 6PGD enzyme activity by enzyme activity assay in OV2008, C13∗, A549, and A549DDP cells. (B) 6PGD mRNA expression levels by qRT-PCR (top) and protein levels by Western blotting (bottom) in OV2008, C13∗, A549, and A549DDP cells. (C) 6PGD protein levels were analyzed in non-tumor ovarian tissues and ovarian cancer tissues. (D) 6PGD protein levels were analyzed in non-tumor lung tissues and lung SCC, lung adenocarcinoma, and large cell lung cancer tissues. (E,F) Kaplan–Meier analysis of OS rates in 34 ovarian cancer patients (E) and 44 NSCLC patients (F) relative to 6PGD protein expression. Error bars represent mean values ± SD from three replicates of each sample (∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001).